文章：

筛状型与导管内型：如何区分差异

Cribriform versus Intraductal: How to Determine the Difference

原文发布日期：24 May 2024

DOI: 10.3390/cancers16112002

类型: Article

开放获取: 是

英文摘要：

Over the years, our understanding of cribriform and intraductal prostate cancer (PCa) has evolved significantly, leading to substantial changes in their classification and clinical management. This review discusses the histopathological disparities between intraductal and cribriform PCa from a diagnostic perspective, aiming to aid pathologists in achieving accurate diagnoses. Furthermore, it discusses the ongoing debate surrounding the different recommendations between ISUP and GUPS, which pose challenges for practicing pathologists and complicates consensus among them. Recent studies have shown promising results in integrating these pathological features into clinical decision-making tools, improving predictions of PCa recurrence, cancer spread, and mortality. Future research efforts should focus on further unraveling the biological backgrounds of these entities and their implications for clinical management to ultimately improve PCa patient outcomes.

摘要翻译： 

多年来，我们对筛状和导管内前列腺癌（PCa）的认识已显著深化，这导致其分类和临床管理方式发生重大变革。本文从诊断角度探讨导管内与筛状前列腺癌的组织病理学差异，旨在帮助病理医师实现精准诊断。同时，文章深入剖析国际泌尿病理学会（ISUP）与泌尿生殖病理学会（GUPS）指南建议分歧引发的持续争议，这些差异给临床病理实践带来挑战，也增加了病理学界达成共识的难度。最新研究表明，将这些病理特征整合到临床决策工具中已取得显著成效，可提升对前列腺癌复发、转移及死亡风险的预测能力。未来研究应着重揭示这些亚型的生物学本质及其临床管理意义，从而最终改善前列腺癌患者的预后。

原文链接：

Cribriform versus Intraductal: How to Determine the Difference